Element Wealth LLC Has $443,000 Stock Holdings in Pfizer Inc. (NYSE:PFE)

Element Wealth LLC grew its stake in Pfizer Inc. (NYSE:PFE) by 5.7% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 15,313 shares of the biopharmaceutical company’s stock after purchasing an additional 830 shares during the quarter. Element Wealth LLC’s holdings in Pfizer were worth $443,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. Global Assets Advisory LLC acquired a new stake in Pfizer in the 1st quarter worth about $725,000. Atlas Capital Advisors LLC boosted its stake in shares of Pfizer by 54.4% in the first quarter. Atlas Capital Advisors LLC now owns 1,702 shares of the biopharmaceutical company’s stock valued at $47,000 after buying an additional 600 shares during the period. 180 Wealth Advisors LLC boosted its stake in shares of Pfizer by 3.1% in the first quarter. 180 Wealth Advisors LLC now owns 28,489 shares of the biopharmaceutical company’s stock valued at $791,000 after buying an additional 857 shares during the period. Hennessy Advisors Inc. grew its position in Pfizer by 2.9% during the first quarter. Hennessy Advisors Inc. now owns 183,800 shares of the biopharmaceutical company’s stock worth $5,100,000 after buying an additional 5,200 shares in the last quarter. Finally, Addenda Capital Inc. raised its holdings in Pfizer by 0.5% in the 1st quarter. Addenda Capital Inc. now owns 199,272 shares of the biopharmaceutical company’s stock valued at $5,530,000 after acquiring an additional 947 shares in the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Trading Down 0.7 %

Shares of NYSE PFE opened at $28.65 on Friday. The firm has a 50 day moving average price of $29.07 and a two-hundred day moving average price of $28.48. The stock has a market cap of $162.35 billion, a P/E ratio of -62.28, a price-to-earnings-growth ratio of 1.01 and a beta of 0.67. Pfizer Inc. has a 52-week low of $25.20 and a 52-week high of $31.54. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.60 and a current ratio of 0.86.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, July 30th. The biopharmaceutical company reported $0.60 earnings per share for the quarter, beating the consensus estimate of $0.46 by $0.14. Pfizer had a positive return on equity of 8.42% and a negative net margin of 4.66%. The company had revenue of $13.28 billion during the quarter, compared to analysts’ expectations of $12.96 billion. During the same quarter in the prior year, the firm posted $0.67 earnings per share. The business’s quarterly revenue was up 2.1% on a year-over-year basis. As a group, equities analysts forecast that Pfizer Inc. will post 2.67 EPS for the current year.

Pfizer Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, December 2nd. Investors of record on Friday, November 8th will be paid a dividend of $0.42 per share. This represents a $1.68 dividend on an annualized basis and a yield of 5.86%. The ex-dividend date is Friday, November 8th. Pfizer’s dividend payout ratio is presently -365.21%.

Analyst Ratings Changes

A number of brokerages recently commented on PFE. StockNews.com upgraded Pfizer from a “hold” rating to a “buy” rating in a research report on Wednesday, October 9th. UBS Group upped their price target on shares of Pfizer from $30.00 to $31.00 and gave the stock a “neutral” rating in a report on Wednesday, July 31st. Sanford C. Bernstein assumed coverage on shares of Pfizer in a research note on Thursday, October 17th. They issued a “market perform” rating and a $32.00 price objective on the stock. Cantor Fitzgerald restated an “overweight” rating and set a $45.00 target price on shares of Pfizer in a research note on Wednesday. Finally, Wells Fargo & Company lifted their price target on Pfizer from $28.00 to $30.00 and gave the company an “equal weight” rating in a research note on Wednesday, July 31st. Seven investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Pfizer has an average rating of “Moderate Buy” and a consensus price target of $33.91.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.